XBiotech Inc. (XBIT)

NASDAQ: XBIT · IEX Real-Time Price · USD
5.59
0.15 (2.76%)
May 27, 2022 4:00 PM EDT - Market closed
Market Cap175.47M
Revenue (ttm)14.04M
Net Income (ttm)-20.24M
Shares Out31.39M
EPS (ttm)-0.67
PE Ration/a
Forward PEn/a
Dividend$2.50 (44.72%)
Ex-Dividend Daten/a
Volume56,389
Open5.42
Previous Close5.44
Day's Range5.36 - 5.63
52-Week Range5.37 - 18.46
Beta1.42
AnalystsBuy
Price Targetn/a
Earnings DateMay 9, 2022

About XBIT

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID...

IndustryBiotechnology
IPO DateApr 15, 2015
CEOJohn Simard
Employees97
Stock ExchangeNASDAQ
Ticker SymbolXBIT
Full Company Profile

Financial Performance

In 2021, XBiotech's revenue was $18.39 million, a decrease of -58.19% compared to the previous year's $44.00 million. Losses were -$17.41 million, 55.2% more than in 2020.

Financial Statements

News

Why Are XBiotech Shares Trading Higher Today

The French authority has signed off XBiotech Inc's (NASDAQ: XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer.  The French National Canc...

4 weeks ago - Benzinga

XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Pha...

ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France ANSM approves NATRUNIX for INSA funded Phase-I-III Study at 20 Leading Medical Centers in France

4 weeks ago - GlobeNewsWire

XBiotech Inks Clinical Manufacturing Deal

XBiotech Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson XBiotech Manufacturing Antibody Drug for Janssen ...

3 months ago - GlobeNewsWire

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

Natrunix-SQ, A True Human Antibody Therapy Discovered and Manufactured at XBiotech, Is Aimed as a Breakthrough Treatment for Arthritic Disease Natrunix-SQ, A True Human Antibody Therapy Discovered and M...

4 months ago - GlobeNewsWire

FDA Approves XBiotech's IND in Rheumatology

Launching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology Launching Novel True Human Antibody Therapy Natrunix™ to Treat Rheumatology

5 months ago - GlobeNewsWire

XBiotech to Launch Novel Candidate Therapy for Stroke

Company Commencing Phase I/II Study to Test Safety and Efficacy of its New Drug Candidate to Reduce Brain Injury After Stroke Company Commencing Phase I/II Study to Test Safety and Efficacy of its New D...

6 months ago - GlobeNewsWire

XBiotech Announces Payment of Dividend to Holders of Common Stock

Company distributed USD $75 Million to Shareholders Company distributed USD $75 Million to Shareholders

9 months ago - GlobeNewsWire

XBiotech Announces Dividend to Holders of Common Stock

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an ...

10 months ago - GlobeNewsWire

XBiotech Announces Receipt of $75 Million from Sale of Antibody

Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody Company Has Now Received a Total of $750 million for Sale of Its True Human Antibody

10 months ago - GlobeNewsWire

XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer

XB2001 Is a Novel Therapy that Interrupts Inflammation to Potentially Block Growth and Spread of Tumors and to Reduce Toxicity of Chemotherapy Treatment XB2001 Is a Novel Therapy that Interrupts Inflamm...

11 months ago - GlobeNewsWire

XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic Cancer

The FDA has signed off Phase 1/2 clinical study to evaluate XBiotech Inc's (NASDAQ: XBIT) XB2001 when added to the ONIVYDE/5-FU combination therapy for treating patients with pancreatic cancer. The Phas...

1 year ago - Benzinga

FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreati...

XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer XBiotech's New Drug to Enter Clinical Studies in Combination Therapy for Pancreatic Cancer

1 year ago - GlobeNewsWire

Top Small-Cap Stocks for March 2021

These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.

1 year ago - Investopedia

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human™ COVID-19 Therapy may be Effective for Treating New Mutant Strain With New Infectious Strain R...

1 year ago - GlobeNewsWire

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy

Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Albers, M.D. and Brett Cucchiara, M.D. Appointments Include: Chair, Clay Johnston, M.D., Ph.D. as well as Members Greg Alb...

1 year ago - GlobeNewsWire

Top Small Cap Stocks for January 2021

These are the small cap stocks with the best value, fastest growth, and most momentum for January 2021.

1 year ago - Investopedia

Top Small Cap Stocks for December 2020

These are the small cap stocks with the best value, fastest growth, and most momentum for December 2020.

1 year ago - Investopedia

XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Thera...

Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential

1 year ago - GlobeNewsWire

Top Small Cap Stocks for November 2020

These are the small cap stocks with the best value, fastest growth, and most momentum for November 2020.

1 year ago - Investopedia

5 Ben Graham Lost Formula Stocks With High Financial Strength

As markets continue sliding on economic recovery slowdown fears, five Ben Graham Lost Formula stocks with high financial strength are Sabine Royalty Trust (NYSE:SBR), XBiotech Inc. (NASDAQ:XBIT), Cataly...

Other symbols:CPRXPRDOSBRVNDA
1 year ago - GuruFocus

Top Small Cap Stocks for October 2020

These are the small cap stocks with the best value, fastest growth, and most momentum for October 2020.

1 year ago - Investopedia

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

With the Arrival of Flu Season, Development of a Breakthrough Therapeutic for Treating Influenza and COVID-19 Co-Infections is Urgently Needed With the Arrival of Flu Season, Development of a Breakthrou...

1 year ago - GlobeNewsWire

Top Biotech Stocks for Q4 2020

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

1 year ago - Investopedia

Top Small Cap Stocks for September 2020

These are the small cap stocks with the best value, fastest growth, and most momentum for September.

1 year ago - Investopedia

XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authoriz...

FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients

1 year ago - GlobeNewsWire